Literature DB >> 12402300

Ectopic expression of herpes simplex virus-thymidine kinase gene in human non-small cell lung cancer cells conferred caspase-activated apoptosis sensitized by ganciclovir.

Chien-Chih Chiu1, Yuan-Lin Kang, Tsung-Hsiang Yang, Chih-Hsin Huang, Kang Fang.   

Abstract

Human non-small cell lung cancer (NSCLC) cells were transfected with recombinant prodrug herpes simplex virus type I thymidine kinase (HSV-tk) cDNA, and the selected clones underwent apoptosis in response to induction by antiviral ganciclovir (GCV). The efficiency of GCV-induced growth inhibition and the extent of the bystander effect were associated with the expression level of HSV-TK in stable transfectants. Development in the HSV-tk/GCV system toward cell death was initiated with cell-cycle accumulation at S and G(2)/M phases, immediately followed by the appearance of sub-G(0)/G(1) cells after drug exposure. To investigate the regulation of cell-cycle modulators during drug treatment, we analyzed release of the apoptosis initiator cytochrome c and activation of the downstream effectors caspase-9, caspase-3 and poly(ADP-ribose)polymerase 16 hr after GCV sensitization, followed by transient escalation of tumor-suppressor p53 and cell-cycle modulators cyclin A and B(1) before committing to programmed cell death. Furthermore, tumor regression was proportional to the degree of ectopic expression of the transferred HSV-tk gene. Our results demonstrate that the HSV-tk/GCV system effectively inhibits the proliferation of NSCLC cells in vitro and in vivo through potent induction of apoptosis, thus providing a rationale for further development. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12402300     DOI: 10.1002/ijc.10701

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.

Authors:  Sung Jin Kim; Ju Hyun Kim; Bitna Yang; Jin-Sook Jeong; Seong-Wook Lee
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

2.  ApoE-modified liposomes mediate the antitumour effect of survivin promoter-driven HSVtk in hepatocellular carcinoma.

Authors:  Xiuli Mu; Xi Wang; Yan Wei; Chaochao Wen; Qi Zhang; Chunyang Xu; Chang Liu; Chan Zhang; Fanxiu Meng; Na Zhao; Tao Gong; Rui Guo; Gongqin Sun; Gaopeng Li; Hongwei Zhang; Qin Qin; Jun Xu; Xiushan Dong; Lumei Wang; Baofeng Yu
Journal:  Cancer Gene Ther       Date:  2019-10-23       Impact factor: 5.987

3.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of esophageal squamous cancers.

Authors:  Yaoping Shi; Jianfeng Wang; Zhibin Bai; Yonggang Li; Longhua Qiu; Bo Zhai; Feng Zhang; Xiaoming Yang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

Review 4.  Age-related cataracts: Role of unfolded protein response, Ca2+ mobilization, epigenetic DNA modifications, and loss of Nrf2/Keap1 dependent cytoprotection.

Authors:  Palsamy Periyasamy; Toshimichi Shinohara
Journal:  Prog Retin Eye Res       Date:  2017-08-31       Impact factor: 21.198

5.  Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells.

Authors:  Hsueh-Wei Chang; Ruei-Nian Li; Hui-Ru Wang; Jing-Ru Liu; Jen-Yang Tang; Hurng-Wern Huang; Yu-Hsuan Chan; Ching-Yu Yen
Journal:  Front Physiol       Date:  2017-09-07       Impact factor: 4.566

6.  From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.

Authors:  Mahsa Saliani; Razieh Jalal; Mohammad Reza Ahmadian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

7.  β2-Adrenergic receptor agonist enhances the bystander effect of HSV-TK/GCV gene therapy in glioblastoma multiforme via upregulation of connexin 43 expression.

Authors:  Saereh Hosseindoost; Seyed Mojtaba Mousavi; Ahmad Reza Dehpour; Seyed Amirhossein Javadi; Babak Arjmand; Ali Fallah; Mahmoudreza Hadjighassem
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.